QIBA SPECT Biomarker Committee (BC)
Friday, July 21, 2017, 9 AM (CT)

Call Summary

Technical details provided by Dr. Miyaoka

In attendance:
- Robert Miyaoka, PhD (Moderator)
- Yuni Dewaraja, PhD (Co-Chair)
- John Seibyl, MD (Co-Chair)
- John Dickson, PhD
- Eric Frey, PhD
- Paul Kinahan, PhD
- Kevin O’Donnell, MASc
- Eric Perlman, MD
- Brian Zimmerman, PhD
- Julie Lisiecki
- Susan Weinmann
- Yuni Dewaraja, PhD (Co-Chair)
- Eric Perlman, MD
- Susan Weinmann

Moderator: Dr. Miyaoka

Call Scheduling

- The next SPECT BC meeting is scheduled for August 18th
- An I-123 Profile Task Force (TF) call will be scheduled for Tuesday, August 1st at 2 pm CT to review comments with Mr. O’Donnell
- As TF calls resume, they will be scheduled as follows:
  - First Tuesday of the month: I-123 (Drs. Seibyl, Dickson, and Miyaoka)
  - Second Tuesday of the month: Technetium Profile (Tc 99m) (Drs. Dewaraja, Miyaoka, and Mozley)
- Technical scribes may be needed for these calls. If interested, please respond to Dr. Mozley (mozley@gmail.com)

Groundwork project updates:

I-123 (Drs. Dewaraja and Dickson):

- Overall, biases were similar between the GE Discovery 670 and the Siemens Intevo system
- Caudate to Putamen ratios were not exactly 1
- Claim 1B may need revision based upon more groundwork testing
- Dr. Frey suggested using more iterations and subsets for quantitative analysis

DRO (Dr. Miyaoka):

- Dr. Miyaoka shared a table of results from different analysis tools used with some hand-drawn volume-of-interest maps (VOIs) and one automated placement
- The number for the specific binding ratio (SBR) needs to be updated
- Once the DRO is revised, Dr. Miyaoka will redistribute it to the BC for analysis; he is particularly interested in results generated by Dr. Seibyl’s Parkinson’s Progression Markers Initiative (PPMI) software
- Additional discussion regarding these results may be needed, along with guidance from Dr. Obuchowski to determine how much variability is acceptable in DRO analysis
- The group discussed using an anonymization approach similar to that of the FDG-PET BC for public sharing of DRO results

SPECT Profile paper under consideration:

- Drs. Kinahan, Perlman, and Frey provided some input from their experience of writing of a paper for the FDG/PET Profile
- Rather than repeat the profile description text from the recent FDG-PET manuscript, the SPECT paper will reference their work
- It was decided that it would be better to write a paper after results are obtained from technical conformance testing, as the FDG-PET group indicated that test results led to revisions in their manuscript
- Additional discussion is needed regarding site testing
  - Multi-site trial would be ideal, but may not be feasible
  - The BC intends to recruit multiple sites to use the profile in their clinical work
I-123 Ioflupane Profile: Next Steps

- Discussion regarding QIBA Profile Stages took place
- It was noted that the name of the stage corresponds to the published document
- Mr. O’Donnell will join the Tuesday Task Force call on August 1st to discuss incorporating his comments made during the public comment phase.

New members
- All are encouraged to recruit new members regularly; new names can be sent to qiba@rsna.org
- Opportunities to meet and recruit new members may present themselves at the following meetings:
  - October, Vienna: EANM annual meeting
  - December, Chicago: RSNA annual meeting
- Volunteers willing to moderate BC or TF calls would be appreciated
  - Please email the SPECT BC co-chairs if interested: yuni@umich.edu; mozley@gmail.com; jseibyl@mnimaging.com
- Previous meeting agendas, Profile versions, and work products are available in the group’s Dropbox folder

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki